Fair trade regulator CCI on Tuesday approved the acquisition of 1.74% equity stake of Lenskart Solutions by Kedaara Capital Fund III LLP. Lenskart Solutions is into the business of eyewear products, while Kedaara Capital Fund III LLP is a Sebi-registered Alternative Investment Fund (AIF). The latter is part of the Kedaara Group.
In a tweet on Tuesday, the Competition Commission of India (CCI) said it has approved “acquisition of approximately 1.74% equity share capital of Lenskart Solutions Pvt Ltd by Kedaara Capital Fund III LLP (Kedaara Group)”.
In another tweet, the regulator said it has cleared the acquisition of a majority stake in Indira IVF by Zonnebaars, owned by BPEA Private Equity Fund VIII.
BPEA Private Equity Fund VIII is an investment fund owned and controlled by Swedish-based EQT AB.
Further, the CCI also approved the amalgamation of Spaceway Wellness into Indira IVF.
The company provides in vitro fertilisation treatment through its hospitals/centres across the country. Spaceway is one of the promoters of Indira IVF.
In July this year, EQT announced that BPEA Private Equity Fund VIII has agreed to acquire a controlling stake in Indira IVF, from TA Associates and Murdia family, who will retain a significant minority stake and continue to lead the company.
Deals beyond a certain threshold require approval from the regulator, which keeps a tab on unfair business practices and promotes fair competition in the marketplace.
